Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer - PubMed
3 hours ago
- #HER2
- #breast cancer
- #trastuzumab deruxtecan
- Trastuzumab deruxtecan (T-DXd) is used for metastatic breast cancer (MBC), but traditional HER2 immunohistochemistry fails to predict its activity.
- T-DXd's effectiveness varies with HER2 expression over time, showing longest activity in HER2-positive or HER2-low disease across primary and metastatic settings.
- Quantitative HER2 assessments (High Sensitivity-HER2, Reverse Phase Protein Array HER2, HER2DX ERBB2 mRNA, plasma DNADX HER2) predict T-DXd performance better than HER2 immunohistochemical subtypes.
- Elevated TOPO1 expression is linked to worse outcomes with T-DXd in HER2-negative breast cancer, suggesting payload-related markers may predict T-DXd performance.
- Multiple authors report competing interests, including consulting fees, research funding, and stock ownership in pharmaceutical and biotech companies.